Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition


Por: Cives-Losada, C, Macias, RIR, Lozano, E, Zanatto, L, Sancho-Bru, P, Martinez-Chantar, ML, Avila, MA, Armengol, C, Cairo, S, Marin, JJG and Briz, O

Publicada: 23 abr 2026 Ahead of Print: 1 abr 2026
Resumen:
Hepatoblastoma (HB) is the most common malignant liver tumor in children. One-fifth of patients exhibit a poor prognosis due to resistance to conventional chemotherapy, which typically includes doxorubicin. One of the underlying mechanisms is drug efflux through the MDR1 export pump. This study aims to explore pharmacological strategies for sensitizing HB by inhibiting MDR1. A panel of compounds, including established MDR1 inhibitors, natural products, clinically used drugs, and tyrosine kinase inhibitors (TKIs), was employed to inhibit MDR1 activity and enhance the response to doxorubicin. Wild-type (HepG2-WT) and doxorubicin-resistant (HepG2-DR) cells, with enhanced MDR1 expression, as well as murine xenograft models and patient-derived HB cells (HB-303) and organoids, were utilized. Curcumin did not sensitize HepG2-DR cells to doxorubicin, whereas verapamil and simvastatin enhanced doxorubicin cytotoxicity only at toxic concentrations. In contrast, several TKIs, including nilotinib, tivozanib, and, to a lesser extent, cabozantinib, exhibited synergistic effects with doxorubicin in HepG2-DR cells. These TKIs also improved the efficacy of doxorubicin in patient-derived HB organoids, a response that depended on MDR1 expression. Third-generation MDR1 inhibitors (tariquidar, elacridar, and zosuquidar) sensitized HepG2-DR and HB-303 cells at non-toxic nanomolar concentrations in vitro. Furthermore, the combination of doxorubicin and zosuquidar significantly reduced tumor growth even when these were generated from chemoresistant cells. In conclusion, we described pharmacological strategies to enhance HB response to chemotherapy. MDR1 inhibitors, such as zosuquidar, may enable dose reductions of chemotherapeutic agents, whereas the use of synergistic TKIs, such as tivozanib, may improve therapeutic outcomes and minimize adverse effects in children with HB.TG100-115, a TRPM7 kinase inhibitor, provides neuroprotection and attenuates NLRP3 inflammasome-mediated neuroinflammation in a neonatal mouse model of hypoxic-ischemic brain injury.

Filiaciones:
Cives-Losada, C:
 Univ Salamanca, Inst Biomed Res Salamanca IBSAL, Expt Hepatol & Drug Targeting HEVEPHARM, Salamanca 37007, Spain

 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain

Macias, RIR:
 Univ Salamanca, Inst Biomed Res Salamanca IBSAL, Expt Hepatol & Drug Targeting HEVEPHARM, Salamanca 37007, Spain

 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain

Lozano, E:
 Univ Salamanca, Inst Biomed Res Salamanca IBSAL, Expt Hepatol & Drug Targeting HEVEPHARM, Salamanca 37007, Spain

 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain

Zanatto, L:
 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer, IDIBAPS, Barcelona 08036, Spain

Sancho-Bru, P:
 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain

 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer, IDIBAPS, Barcelona 08036, Spain

Martinez-Chantar, ML:
 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain

 Basque Res & Technol Alliance BRTA, Liver Dis Lab, Ctr Cooperat Res Biosci, CICbioGUNE, Bizkaia Technol Pk,Bldg 801A, Derio 48160, Bizkaia, Spain

Avila, MA:
 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain

 Univ Navarra, Solid Tumors Program, Hepatol Lab, Inst Invest Sanit Navarra IdiSNA,CIMA,CCUN, Pamplona 31008, Spain

:
 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain

 Germans Trias i Pujol Res Inst IGTP, Translat Program Canc Res CARE, Childhood Liver Oncol Grp, Badalona 08916, Spain

Cairo, S:
 Champ Oncol, Rockville, MD USA

Marin, JJG:
 Univ Salamanca, Inst Biomed Res Salamanca IBSAL, Expt Hepatol & Drug Targeting HEVEPHARM, Salamanca 37007, Spain

 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain

Briz, O:
 Univ Salamanca, Inst Biomed Res Salamanca IBSAL, Expt Hepatol & Drug Targeting HEVEPHARM, Salamanca 37007, Spain

 Carlos III Natl Inst Hlth, Ctr Study Liver & Gastrointestinal Dis CIBERehd, Madrid 28029, Spain
ISSN: 16714083





Acta Pharmacologica Sinica
Editorial
Nature Publishing Group, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, China
Tipo de documento: Article
Volumen: Número:
Páginas:
WOS Id: 001746918200001
ID de PubMed: 42026237
imagen hybrid

MÉTRICAS